| NEW
YORK, Oct. 6 /PRNewswire-FirstCall/ -- Pfizer (NYSE: PFE) today announced the
completion of its acquisition of FoldRx Pharmaceuticals, Inc., a privately held
drug discovery and clinical development company. FoldRx
Pharmaceuticals, Inc. is now a wholly owned subsidiary of Pfizer Inc. Pfizer
Inc: Working together for a healthier world(TM) At
Pfizer, we apply science and our global resources to improve health and well-being
at every stage of life. We strive to set the standard for quality, safety and
value in the discovery, development and manufacturing of medicines for people
and animals. Our diversified global health care portfolio includes human and animal
biologic and small molecule medicines and vaccines, as well as nutritional products
and many of the world's best-known consumer products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness, prevention, treatments
and cures that challenge the most feared diseases of our time. Consistent with
our responsibility as the world's leading biopharmaceutical company, we also collaborate
with health care providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For more than 150
years, Pfizer has worked to make a difference for all who rely on us. To learn
more about our commitments, please visit us at www.pfizer.com More
information is available at www.pfizer.com. Follow
Pfizer on www.Twitter.com/pfizer_news. SOURCE
Pfizer Inc.
|